Find information on thousands of medical conditions and prescription drugs.

Juvenile rheumatoid arthritis

Juvenile arthritis is a type of arthritis typically affects children before the age of sixteen. Most children with juvenile arthritis have a form of rheumatoid arthritis, the symptoms of which are identical to the adult kind. In many cases the condition is outgrown at a later age. Juvenile rheumatoid arthritis can occur as early as six weeks of age and occurs in girls more commonly than boys. There are three primary types of juvenile rheumatoid arthritis: Polyarticular, pauciarticular, and systemic. more...

 Home
Diseases
A
B
C
D
E
F
G
H
I
J
Jackson-Weiss syndrome
Jacobs syndrome
Jacobsen syndrome
Japanese encephalitis
Johnson Munson syndrome
Joubert syndrome
Jumping Frenchmen of Maine
Juvenile dermatomyositis
Juvenile rheumatoid...
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines
  • Polyarticular involves more than five joints and may be associated with a low grade fever.
  • Pauciarticular, as the name implies, involves fewer joints (fewer than 4).
  • Systemic juvenile rheumatoid arthritis can affect the entire body.

High fevers may occur and tend to rise during the day and fall at night. Disease modifying antirheumatic drugs (DMARDS) may be able to slow the progression the disease. Newer medications such as anti-TNF alpha and anti-IL 1 drugs may also prove to be of significant help for juvenile rheumatoid arthritis.

Read more at Wikipedia.org
• [List your site here Free!]

Delayed-Release Drug for Juvenile Rheumatoid Arthritis - Azulfidine EN-tabs
From American Family Physician, 3/15/01 by Monica Preboth

Sulfasalazine delayed-release tablets (Azulfidine EN-tabs) have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children six through 16 years of age with juvenile rheumatoid arthritis involving five or more diseased joints who have not responded adequately to salicylates or other nonsteroidal anti-inflammatory drugs. The tablets are the only formulation of sulfasalazine approved by the FDA for the treatment of juvenile and adult rheumatoid arthritis.

According to the manufacturer of sulfasalazine, rheumatoid arthritis is a debilitating disease that affects 50,000 children in the United States. The disease causes joint pain, stiffness and swelling in or around joints, and joint destruction.

In clinical trials, sulfasalazine significantly reduced the number and severity of swollen joints, the number of active joints and overall joint severity score. There was also a significant reduction in disease activity scored by physicians, parents and patients.

Sulfasalazine delayed-release tablets are enteric coated to reduce the likelihood of nausea and stomach upset. The most common side effects of sulfasalazine are nausea, dyspepsia, rash, immunoglobulin suppression, headache, abdominal pain, vomiting and fever. Patients who have intestinal or urinary obstructions, porphyria or hypersensitivity to sulfasalazine, sulfonamides or salicylates should not use sulfasalazine delayed-release tablets.

COPYRIGHT 2001 American Academy of Family Physicians
COPYRIGHT 2001 Gale Group

Return to Juvenile rheumatoid arthritis
Home Contact Resources Exchange Links ebay